ArticleDiscover oncology2025
LncRNA B4GALT 1-AS1/miR-144-3p axis suppresses cytotoxicity of CD8
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in miRNA-Mediated Bidirectional Crosstalk and Immune Evasion Mechanisms Between Lung Cancer Cells and CD8International journal of molecular sciences · 2026Review
- Identification of hsa-miR-144-3p as a novel immunotherapeutic target for glioblastoma based on disulfidptosis-related analysis.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFor lung adenocarcinoma (LUAD), which has the highest mortality rate among cancers, the current known immunotherapy has only achieved limited results. This article aimed to clarify the novel immune escape mechanism in LUAD based on the long non-coding RNA (lncRNA)-microRNA (miRNA) network.
methodsBy bioinformatics analysis, the expression of B4GALT1-AS1 and miR-144-3p was determined and the binding sites were predicted. RNA immunoprecipitation assay, dual-luciferase assay, and RNA pull-down experiment were employed to validate their binding. Quantitative reverse transcription polymerase chain reaction was utilized to measure the expression levels. LUAD cell proliferation and cell cycle progression were detected by Colony formation assay and cell cycle analysis. Cell migration and invasion were detected by Transwell assay. A co-culture system evaluated the proportion of IFN-γ positive CD8
resultsIn LUAD, B4GALT1-AS1 was highly expressed, while miR-144-3p was lowly expressed. B4GALT1-AS1 facilitated LC cell proliferation, migration, invasion, inhibited CD8
conclusionThis study demonstrated that the B4GALT1-AS1/miR-144-3p axis suppressed the cytotoxicity of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.